See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Products
GBI Health Data Intelligence Suite
Solutions
Full Life-Cycle Solutions for Pharmaceuticals
Powered by global drug pipeline data, the Competitive Landscape Analysis solution enables multidimensional analysis across drugs, targets, indications, and technologies. It helps R&D teams identify strategic opportunities, prioritize investments, and make more informed development decisions.
Drawing on data from six major global clinical trial registries, the Clinical R&D Insights solution provides deep visibility into global trial activity and protocol designs, helping teams optimize clinical development strategies and trial execution.
Drawing on data covering the National Reimbursement Drug List (NRDL), public procurement and tendering, Huiminbao (commercial health insurance), Patient Assistance Programs (PAPs), and healthcare policies and regulations, the Market Access Strategy solution supports market access planning, pricing analysis, and regional opportunity assessment to accelerate commercialization and market access.
Built on comprehensive researcher profiles, the GBI KOL/HCP Management solution enables researcher identification, segmentation, academic influence analysis, and collaboration network mapping, helping Medical Affairs, Marketing, and Sales teams improve researcher engagement and operational efficiency.
Industry News and Reports
Aggregating industry news and in-depth reports to help pharma companies stay ahead.
- LEO Pharma’s delgocitinib approved for marketing in China
On November 13, 2026, LEO Pharma announced that Anzupgo (delgocitinib cream) has been approved by China’s National Medical Products Administration (NMPA) for the topical treatment of moderate-to-severe chronic hand eczema (CHE) in adults for whom topical corticosteroids are inadequate or inappropriate.
- Exegenesis Bio and Ascidian enter into collaboration on RNA exon editing therapies
On November 13, 2026, Hangzhou-based Exegenesis Bio and Ascidian Therapeutics announced a strategic agreement to integrate Ascidian’s RNA exon editing technology with Exegenesis Bio’s capsid engineering and development platform, aiming to develop novel delivery strategies tailored to the clinical needs of various pipelines.
- Autobio and Haier Biomedical Join Forces to Advance Smart Laboratory Construction
Autobio Diagnostics Co., Ltd. (hereinafter referred to as "Autobio") and Haier Biomedical (hereinafter referred to as "Haier Biomedical") signed a strategic cooperation agreement on November 10, 2026.
- New R&D progress on TenNor Therapeutics’ anti-infective drugs
On November 12, 2026, TenNor Therapeutics (6872.HK) announced multiple key R&D milestones for its two core products, rifasutenizol (TNP-2198) and rifaquinone (TNP-2092).
- Walvax and CureGene Join Forces to Build a Collaborative R&D System for Innovative Nucleic Acid Drugs
On November 12, 2026, CureGene and Walvax announced the signing of a strategic cooperation memorandum of understanding.
- Youcare Pharmaceutical's YKYY018 receives IND approval from U.S. FDA
On November 13, 2026, Youcare Pharmaceutical (688658.SH) announced that its YKYY018 inhalation solution recently received Investigational New Drug (IND) approval from the U.S. FDA for clinical trials aimed at the treatment and prevention of human parainfluenza virus (HPIV) infection.
In-Depth, Exclusive Industry Reports
Curated by expert analysts, offering in-depth analysis of emerging industry trends and the competitive landscape.
Scan the QR code to follow the GBIHealth WeChat Official Account for industry news, live webinars, thematic reports, and more.
Reliable partner for 95%+ key global medical industry players
Our clients are drawn from across pharma, medical device firms, CROs/CDMOs, investors, consulting firms, and others
See the Whole Landscape Shape What's Next in Pharma
GBI Health unites global pharmaceutical data, AI capabilities and industry expertise to deliver future-ready solutions across the entire product lifecycle.
Contact Us